Correction of hemophilia B in canine and murine models using recombinant adeno-associated viral vectors
Richard O. Snyder, Carol H. Miao, Leonard Meuse et al. · Nature Medicine · 1999
Cited by 409 works. doi:10.1038/4751
Authors
- Richard O. Snyder
- Carol H. Miao
- Leonard Meuse
- Julie Tubb
- Brian A. Donahue
- Hui-Feng Lin
- Darrel W. Stafford
- Salil D. Patel
- Arthur R. Thompson
- Timothy C. Nichols
- Marjorie S. Read
- Dwight A. Bellinger
- Kenneth M. Brinkhous
- Mark A. Kay
References
- Vaccination with irradiated tumor cells engineered to secrete murine granulocyte-macrophage colony-stimulating factor stimulates potent, specific, and long-lasting anti-tumor immunity.
- Helper-free stocks of recombinant adeno-associated viruses: normal integration does not require viral gene expression
- A "humanized" green fluorescent protein cDNA adapted for high-level expression in mammalian cells
- Cellular and humoral immune responses to adenoviral vectors containing factor IX gene: tolerization of factor IX and vector antigens allows for long-term expression.
- Persistent and therapeutic concentrations of human factor IX in mice after hepatic gene transfer of recombinant AAV vectors
- Adenovirus mediated expression of therapeutic plasma levels of human factor IX in mice
- Stable gene transfer and expression of human blood coagulation factor IX after intramuscular injection of recombinant adeno-associated virus
- Targeted disruption of the mouse factor VIII gene produces a model of haemophilia A
- In Vivo Gene Therapy of Hemophilia B: Sustained Partial Correction in Factor IX-Deficient Dogs
- In vivo hepatic gene therapy: complete albeit transient correction of factor IX deficiency in hemophilia B dogs.